<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615615</url>
  </required_header>
  <id_info>
    <org_study_id>N159</org_study_id>
    <nct_id>NCT00615615</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures</brief_title>
  <official_title>Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to&#xD;
      evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial&#xD;
      onset seizures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1999</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial onset seizure frequency (Type I, Type IC included) per week during the Treatment period</measure>
    <time_frame>During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% responder rate in seizure frequency per week during the Treatment Period</measure>
    <time_frame>During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>Response rate is defined as percent of patients experiencing at least a 50% reduction from baseline in the seizure frequency per week during the Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with categorized reduction from baseline in seizure frequency per week during the Treatment Period</measure>
    <time_frame>From Baseline to the 14-weeks Treatment period</time_frame>
    <description>Categories as follows: &lt;-25%, -25% to &lt;25%, 25% to &lt;50%, 50% to &lt;75%, 75% to &lt;100%, and 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the average duration of seizure free intervals</measure>
    <time_frame>From Baseline to the 14-weeks Treatment period</time_frame>
    <description>Intervals are defined as seizure-free if no seizures are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seizure free days during the Treatment Period</measure>
    <time_frame>During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>A day is regarded as seizure-free if no seizures are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in partial onset seizure frequency per week during the Treatment Period</measure>
    <time_frame>Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>Absolute change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in partial onset seizure frequency per week during the Titration Period</measure>
    <time_frame>Baseline, During the 6-weeks Titration period (Week 8 to Week 14)</time_frame>
    <description>Absolute change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in partial onset seizure frequency per week during the Evaluation Period</measure>
    <time_frame>Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)</time_frame>
    <description>Absolute change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in partial onset seizure frequency per week during the Treatment Period</measure>
    <time_frame>Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>Percent change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in partial onset seizure frequency per week during the Titration Period</measure>
    <time_frame>Baseline, During the 6-weeks Titration period (Week 8 to Week 14)</time_frame>
    <description>Percent change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in partial onset seizure frequency per week during the Evaluation Period</measure>
    <time_frame>Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)</time_frame>
    <description>Percent change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period.&#xD;
A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative percentage of patients who were seizure-free since the beginning of the Evaluation Period</measure>
    <time_frame>Beginning of the Evaluation Period (Week 14)</time_frame>
    <description>A subject was regarded as seizure-free if not seizures were reported since the beginning of the Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial onset seizure frequency per week during the Titration Period</measure>
    <time_frame>During the 6-weeks Titration period (Week 8 to Week 14)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial onset seizure frequency per week during the Evaluation Period</measure>
    <time_frame>During the 6-weeks Evaluation period (Week 8 to Week 14)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total seizure frequency per week (Types I + II + III) during the Treatment Period</measure>
    <time_frame>During the 14-weeks Treatment period (Week 8 to Week 22)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total seizure frequency per week (Types I + II + III) during the Titration Period</measure>
    <time_frame>During the 6-weeks Titration period (Week 8 to Week 14)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total seizure frequency per week (Types I + II + III) during the Evaluation Period</measure>
    <time_frame>During the 6-weeks Evaluation period (Week 8 to Week 14)</time_frame>
    <description>Calculated as 7-day partial onset seizure frequency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam (LEV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received Placebo matching to LEV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg&#xD;
low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less</description>
    <arm_group_label>Levetiracetam (LEV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not&#xD;
             secondarily generalized, and the diagnosis was &gt;= 6 months before the Selection Visit&#xD;
&#xD;
          -  epilepsy was classifiable according to the ILAE Classification&#xD;
&#xD;
          -  &gt;= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were&#xD;
             required to have &gt;= 4 partial onset seizures during each 4-week interval of the&#xD;
             Baseline Period to qualify for randomization&#xD;
&#xD;
          -  unsatisfactory current AED treatment in terms of efficacy and/or safety&#xD;
&#xD;
          -  stable AED treatment consisting of no more than two AEDs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treatable seizure etiology&#xD;
&#xD;
          -  epilepsy secondary to a progressive cerebral disease or any other progressively&#xD;
             neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases&#xD;
&#xD;
          -  history of status epilepticus which required hospitalization during 3 months prior to&#xD;
             the Selection Visit&#xD;
&#xD;
          -  history of or the presence of pseudo seizures&#xD;
&#xD;
          -  current diagnosis of Lennox-Gastaut syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N159_CSS_20080318.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <reference>
    <citation>Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z; N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006 Jun 13;66(11):1654-60. Epub 2006 Apr 26.</citation>
    <PMID>16641323</PMID>
  </reference>
  <reference>
    <citation>Jensen FE, Bourgeois BF. Randomized trial supports use of levetiracetam adjunctive therapy to treat partial seizures in children. Nat Clin Pract Neurol. 2006 Nov;2(11):596-7.</citation>
    <PMID>17057745</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <organization>UCB</organization>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

